ORVEPITANT ( DrugBank: Orvepitant )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
85	特発性間質性肺炎	2

85. 特発性間質性肺炎

---

臨床試験数 : 627 /  薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-006278-22-NL (EUCTR)	29/08/2022	01/06/2022	A study to find out if orvepitant is safe to use and reduces the severity of cough in patients with idiopathic pulmonary fibrosis	A DOUBLE-BLIND, RANDOMISED, PLACEBO CONTROLLED, TWO PERIOD CROSS-OVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORVEPITANT IN CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS	Chronic cough in patients with idiopathic pulmonary fibrosis MedDRA version: 21.1;Level: LLT;Classification code 10066656;Term: Chronic cough;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Product Name: Orvepitant INN or Proposed INN: ORVEPITANT Product Name: Orvepitant INN or Proposed INN: ORVEPITANT	NeRRe Therapeutics Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	108	Phase 2	United States;Netherlands;United Kingdom
2	NCT05185089 (ClinicalTrials.gov)	August 1, 2022	23/12/2021	Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis	A Double-Blind, Randomised, Placebo Controlled, Two Period Cross-Over Study to Evaluate the Efficacy and Safety of Orvepitant in Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis	Cough;Idiopathic Pulmonary Fibrosis	Drug: Orvepitant Maleate;Drug: Placebo	Nerre Therapeutics Ltd.	Pharm-Olam International	Recruiting	40 Years	N/A	All	88	Phase 2	United States;Netherlands;United Kingdom